<DOC>
	<DOCNO>NCT02194075</DOCNO>
	<brief_summary>Explore efficacy methylphenidate hydrochloride controlled-release tablet add-on pharmacotherapy clinical symptomatology cognitive functioning sample patient obsessive-compulsive disorder ( OCD ) receive fluvoxamine maleate . To test hypothesis methylphenidate hydrochloride controlled-release tablet augmentation fluvoxamine treatment well tolerate may propose effective therapeutic strategy improve outcome OCD .</brief_summary>
	<brief_title>Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy Patients With Obsessive Compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<criteria>Informed consent Met DSMV criterion YBOCS ≥ 16 Course illness ≥ 1year Age range 18~40 year old Junior high school education level Any psychiatric axisI axisII disorder History epileptic seizure neurological disorder Any clinically relevant abnormality medical history laboratory examination ; alcohol drug abuser</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>